Louisiana State Employees Retirement System Invests $431,000 in Charles River Laboratories International, Inc. $CRL

Louisiana State Employees Retirement System acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the first quarter, Holdings Channel reports. The institutional investor acquired 2,500 shares of the medical research company’s stock, valued at approximately $431,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Invesco Ltd. grew its stake in shares of Charles River Laboratories International by 115.8% during the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after buying an additional 1,446,972 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new position in shares of Charles River Laboratories International in the fourth quarter worth about $176,478,000. Victory Capital Management Inc. lifted its stake in shares of Charles River Laboratories International by 9,938.8% in the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock valued at $137,935,000 after acquiring an additional 684,586 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Charles River Laboratories International by 1,491.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock valued at $96,005,000 after acquiring an additional 575,039 shares during the last quarter. Finally, National Bank of Canada FI boosted its holdings in Charles River Laboratories International by 117.7% during the 3rd quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock valued at $148,131,000 after acquiring an additional 511,901 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Down 2.0%

Shares of NYSE:CRL opened at $224.07 on Thursday. Charles River Laboratories International, Inc. has a 1 year low of $144.26 and a 1 year high of $236.62. The company has a market cap of $10.79 billion, a PE ratio of -59.59, a P/E/G ratio of 2.61 and a beta of 1.40. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03. The stock’s 50-day moving average is $185.01 and its 200 day moving average is $185.28.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The business had revenue of $995.83 million during the quarter, compared to analysts’ expectations of $977.46 million. During the same quarter last year, the business posted $2.34 EPS. The business’s revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 EPS for the current year.

Insider Activity at Charles River Laboratories International

In related news, Director James C. Foster sold 75,000 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the completion of the transaction, the director owned 31,596 shares in the company, valued at $7,109,100. This represents a 70.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

CRL has been the topic of several recent research reports. BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a research report on Wednesday, July 1st. Mizuho set a $192.00 price objective on Charles River Laboratories International in a research note on Friday, May 8th. Weiss Ratings upgraded shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. Morgan Stanley upgraded shares of Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $185.00 to $220.00 in a report on Wednesday, June 17th. Finally, Barclays lifted their target price on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $215.88.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.